The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on JNJ stock, giving a Buy rating on January 8.Stay Ahead of the ...

Connected medical devices can dramatically improve how ... A few months later, Johnson & Johnson warned 114,000 customers that its Animus OneTouch Ping insulin pump had a security flaw that ...